U.S. markets close in 4 hours 21 minutes
  • S&P 500

    4,230.21
    -53.53 (-1.25%)
     
  • Dow 30

    33,721.49
    -277.55 (-0.82%)
     
  • Nasdaq

    12,712.38
    -252.96 (-1.95%)
     
  • Russell 2000

    1,954.35
    -46.38 (-2.32%)
     
  • Crude Oil

    90.93
    +0.43 (+0.48%)
     
  • Gold

    1,761.90
    -9.30 (-0.53%)
     
  • Silver

    19.01
    -0.45 (-2.33%)
     
  • EUR/USD

    1.0049
    -0.0043 (-0.42%)
     
  • 10-Yr Bond

    2.9920
    +0.1120 (+3.89%)
     
  • GBP/USD

    1.1810
    -0.0122 (-1.03%)
     
  • USD/JPY

    137.0100
    +1.1480 (+0.84%)
     
  • BTC-USD

    21,386.05
    -2,076.27 (-8.85%)
     
  • CMC Crypto 200

    507.58
    -34.02 (-6.28%)
     
  • FTSE 100

    7,544.00
    +2.15 (+0.03%)
     
  • Nikkei 225

    28,930.33
    -11.77 (-0.04%)
     

RBC Capital Lowers Inovio Price Target As It Awaits This

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • RBC Capital Markets has lowered the price target on Inovio Pharmaceuticals Inc (NASDAQ: INO) to $4 from $5 with a Sector Perform rating.

  • The analysts updated the model to reflect the evolution of the programs to date and as new leadership gained traction since the CEO change in May.

  • With the CEO transition in conjunction with a new CMO hire, INO-4800’s heterologous booster strategy, VGX-3100’s continued development, and INO-5401 data at ASCO 2022 last month, RBC awaits a more attractive entry point and a clearer path for value creation.

  • Related: Inovio Lays Out Corporate Reorganization To Extend Cash Runway Into 2024.

  • At ASCO 2022, INO presented data on INO-5401 in combination with INO-9012 and Libtayo for newly diagnosed glioblastoma (GBM), with a median overall survival (OS) of 17.9 months and 32.5 months, for Cohort A (unmethylated MGMT) and Cohort B (MGMT methylated) patients, respectively.

  • Overall, the treatment was also well tolerated.

  • The analysts anticipate an update on INO-5401 in 2022 for the next steps towards a regulatory pathway to approval in the combination regimen.

  • RBC views topline data of INO-3107 from Phase 1/2 trial from recurrent respiratory papillomatosis patients as an increasingly important program as value potential embedded in other historically emphasized programs peels away from INO’s core.

  • Price Action: INO shares are up 5.71% at $1.95 during the market session on the last check Tuesday.

Latest Ratings for INO

Date

Firm

Action

From

To

Mar 2022

RBC Capital

Maintains

Sector Perform

Jan 2022

B of A Securities

Upgrades

Underperform

Neutral

Nov 2021

RBC Capital

Maintains

Sector Perform

View More Analyst Ratings for INO

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.